http://www.reuters.com/finance/stocks/...amp;timestamp=20101209133100
Latest Key Developments
Novelos Therapeutics, Inc. Announces Presentation Of Positive Phase II Results In NOV-002 Neoadjuvant Breast Cancer Trial At San Antonio Breast Cancer Symposium
8:31am EST
Novelos Therapeutics, Inc. announced that a poster highlighting positive results in a Phase II trial of NOV-002 in combination with neoadjuvant chemotherapy treatment in patients with stage IIB-IIIC HER-2/neu negative invasive breast cancer is being presented by the Braman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine at the AACR Breast Cancer Symposium in San Antonio, TX. Alberto Montero, MD, Assistant Professor of Medicine at the Miller School and medical oncologist at Sylvester, is the Principal Investigator. The poster, Phase II study of neoadjuvant treatment with cellular redox modulator NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel (AC-T) in patients with stage II-III HER-2(-) breast cancer. The Phase II open-label, single-arm, Simon 2-Stage breast cancer trial was designed to determine if preoperative administration of NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel (AC-T) results in at least a doubling in the rate of pathologic complete response (pCR) compared to a historical control. The trial efficacy criterion of 12 pCRs was met in July 2010 prior to all patients completing the trial. -----------
Nimm Verluste mit Humor. Dein Geld ist nicht weg.
Es hat nur ein Anderer |
